Teva: 'Too early' to say whether merger triggers job cuts

Teva Pharmaceutical Industries ($TEVA) says recent reports of up to 1,500 job cuts from the integration of its recent acquisition, Cephalon, "came from unsubstantiated sources." A U.S. spokeswoman told the Daily Local it's too early to know how the merger will affect Teva and Cephalon employees. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.